Author

Patricia Graham

Observed names: P. Graham, Patricia S Graham, Patricia Sandra Graham

Observed institutions: Holy Cross Hospital, John H. Stroger, Jr. Hospital of Cook County, Mount Sinai Medical Center, Sarah Cannon, Cancer Research And Biostatistics, Sylvester Comprehensive Cancer Center, Cook County Health and Hospitals System, Case Western Reserve University, University of California, Davis

OpenAlex ID: A5113905474

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers

2021 · Michael L. Wang, Jacqueline C. Barrientos, et al. · NEJM Evidence · 83

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6

2007 · Paul J. Hesketh, Rogerio C. Lilenbaum, et al. · Journal of Thoracic Oncology · 51

A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer

2007 · Rogerio Lilenbaum, Mark Rubin, et al. · Journal of Thoracic Oncology · 40

A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC)

2004 · R. Lilenbaum, M. Rubin, et al. · Journal of Clinical Oncology · 25

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

2020 · Michael Wang, Jacqueline C. Barrientos, et al. · Blood · 17

Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC)

2006 · E. Davila, R. Lilenbaum, et al. · Journal of Clinical Oncology · 14

Chemotherapy in patients ≥ 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6

2005 · P. J. Hesketh, R. Lilenbaum, et al. · Journal of Clinical Oncology · 11

Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.

2020 · Catherine S. Magid Diefenbach, Jonathan B Cohen, et al. · Journal of Clinical Oncology · 8

A tool to help research programs exceed the minimum standards of conducting clinical research.

2014 · Patricia Sandra Graham, Renee Yvonne Smith, et al. · Journal of Clinical Oncology

RT11: Targeted Alpha Therapy for Melanoma: From Bench to Bedside

2001 · BJ Allen, Sma Rizvi, et al. · Australasian Physical & Engineering Sciences in Medicine

Works count: 10

Citation count: 249

H-index: 8

I10-index: 7